Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2015 from OUS - The Lipid Clinic

12 publications found

Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, Kastelein JJ, PASCAL Study Group (2015)
Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk
J Pediatr, 167 (2), 338-43.e5
DOI 10.1016/j.jpeds.2015.05.006, PubMed 26059337

Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Wiegman A, Turner T, Kusters DM, Miller E, Raichlen JS, Wissmar J, Martin PD, Stein EA, Kastelein JJP (2015)
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
J Clin Lipidol, 9 (6), 741-750
DOI 10.1016/j.jacl.2015.07.011, PubMed 26687694

Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y (2015)
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
Lancet, 385 (9983), 2153-61
DOI 10.1016/S0140-6736(14)62115-2, PubMed 25743173

Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M (2015)
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
Eur Heart J, 36 (43), 2996-3003
DOI 10.1093/eurheartj/ehv370, PubMed 26330422

Koopal C, Retterstøl K, Sjouke B, Hovingh GK, Ros E, de Graaf J, Dullaart RP, Bertolini S, Visseren FL (2015)
Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study
Atherosclerosis, 240 (1), 90-7
DOI 10.1016/j.atherosclerosis.2015.02.046, PubMed 25768710

Krogh HW, Mundal L, Holven KB, Retterstøl K (2015)
Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death
Eur Heart J, 37 (17), 1398-405
DOI 10.1093/eurheartj/ehv602, PubMed 26586781

Langslet G, Bogsrud MP, Halvorsen I, Fjeldstad H, Retterstøl K, Veierød MB, Ose L (2015)
Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood
J Clin Lipidol, 9 (6), 778-785
DOI 10.1016/j.jacl.2015.08.008, PubMed 26687698

Langslet G, Emery M, Wasserman SM (2015)
Evolocumab (AMG 145) for primary hypercholesterolemia
Expert Rev Cardiovasc Ther, 13 (5), 477-88
DOI 10.1586/14779072.2015.1030395, PubMed 25824308

Narverud I, van Lennep JR, Christensen JJ, Versmissen J, Gran JM, Iversen PO, Aukrust P, Halvorsen B, Ueland T, Ulven SM, Ose L, Veierød MB, Sijbrands E, Retterstøl K, Holven KB (2015)
Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia
Atherosclerosis, 243 (1), 155-60
DOI 10.1016/j.atherosclerosis.2015.09.014, PubMed 26386212

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators (2015)
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
N Engl J Med, 372 (16), 1489-99
DOI 10.1056/NEJMoa1501031, PubMed 25773378

Schernthaner G, Durán-Garcia S, Hanefeld M, Langslet G, Niskanen L, Östgren CJ, Malvolti E, Hardy E (2015)
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
Diabetes Obes Metab, 17 (7), 630-8
DOI 10.1111/dom.12461, PubMed 25761977

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK et al. (2015)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
Eur Heart J, 36 (36), 2425-37
DOI 10.1093/eurheartj/ehv157, PubMed 26009596

 
Page visits: 70970